Treatment-Resistant Anxiety

The short version

●Treatment-resistant anxiety is the anxiety analog to treatment-resistant depression: failure of adequate trials of multiple anxiolytics, SSRIs/SNRIs, and CBT in generalized anxiety disorder, panic disorder, social anxiety disorder, or related conditions.
●No single accepted definition exists. Working definition: failure to achieve adequate response (typically ≥50% symptom reduction) after two or more adequate trials of first-line anxiolytic pharmacotherapy from different classes plus a course of evidence-based CBT.
●Less FDA-acknowledged than TRD; no esketamine equivalent currently approved for anxiety. Clinical reality of treatment-resistant anxiety is widely recognized in practice.
●Treatment-resistant anxiety frequently coexists with treatment-resistant depression, complex PTSD, or treatment-resistant insomnia — these often share underlying dysregulation patterns and respond to overlapping treatment strategies.
●Escalation strategies: switch within and across drug classes (SSRI → SNRI → TCA → MAOI); augmentation (pregabalin, gabapentin, hydroxyzine, low-dose atypical antipsychotic); ACT or schema therapy when CBT plateaus; rapid-acting options including ketamine for the depressive symptoms that often accompany resistant anxiety.
●The Mills 2025 BJPsych ketamine-for-adult-depression analysis demonstrated measurable anxiety reduction alongside antidepressant effect, supporting ketamine's broader anxiolytic mechanism with relevance to treatment-resistant anxiety presentations.

Clinical definition

Treatment-resistant anxiety does not have a single accepted definition. The most useful working definition parallels TRD: failure to achieve adequate response after at least two adequate trials of anxiolytic pharmacotherapy from different mechanistic classes, plus a course of evidence-based cognitive-behavioral therapy with exposure components when relevant. "Adequate" requires therapeutic dose, sufficient duration (8-12 weeks at therapeutic dose for SSRIs/SNRIs in anxiety), and confirmed adherence. The construct applies to any of the primary anxiety disorders — generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), specific phobia, separation anxiety disorder — and is also applied colloquially to anxiety symptoms in PTSD and OCD though those have their own treatment-resistance constructs. Estimated prevalence in the broader anxiety population: 30-40% of patients with primary anxiety disorders meet some operational definition of treatment resistance over the course of their treatment. Comorbidity with depression is the norm rather than the exception in treatment-resistant anxiety, which has significant treatment implications (rapid-acting agents like ketamine are often justified by the depressive component even when the anxiety is the patient's primary concern).

How it differs from related conditions

vs. First-line generalized anxiety / panic / social anxiety

First-line presentations have not yet had two adequate trials of pharmacotherapy plus CBT. The treatment-resistant designation requires the documented failure history. Many patients labeled treatment-resistant have not actually completed adequate trials.

vs. Pseudoresistant anxiety

Patients labeled as treatment-resistant who actually have sub-therapeutic dosing (especially common in anxiety where physicians may under-dose for fear of activation), inadequate duration, undisclosed substance use (caffeine, alcohol, cannabis), undiagnosed medical contributors (hyperthyroidism, supraventricular tachycardia), or undiagnosed comorbidity (sleep apnea, ADHD). Distinguishing matters because pseudoresistant anxiety often responds to properly executed first-line care.

vs. Treatment-resistant depression (TRD)

TRD has its own established literature and FDA-acknowledged treatments (esketamine). Treatment-resistant anxiety has less FDA-acknowledged framework. Many patients meet both — anxious depression is a well-characterized subtype that may respond to overlapping treatments. The clinical question of which is "primary" often matters less than addressing both with overlapping interventions.

vs. OCD (treatment-resistant)

Treatment-resistant OCD has its own established framework (higher-dose SSRIs, clomipramine, exposure with response prevention, augmentation with atypical antipsychotic, ketamine, DBS). The OCD treatment trajectory differs from general anxiety treatment-resistance enough to be considered separately.

First-line treatments

Optimize SSRIs (switch within class)

After failure of one SSRI in anxiety, switching to a different SSRI is reasonable — patients can respond to one specific molecule but not another within the class. Try paroxetine, sertraline, escitalopram, or fluvoxamine. Standard antidepressant titration considerations; start low in anxiety to minimize initial activation that can undermine adherence.

Switch to SNRIs (venlafaxine, duloxetine)

SNRIs have FDA approval in multiple anxiety disorders (venlafaxine in GAD, SAD, panic; duloxetine in GAD). Useful second-line option after SSRI failures. BP monitoring at higher venlafaxine doses. Same start-low principle as in primary anxiety treatment.

Pregabalin or gabapentin

Pregabalin has FDA approval for GAD in Europe but not the U.S.; off-label use in U.S. is established. Effective in GAD with effect sizes comparable to SSRIs. Side effects (sedation, weight gain, cognitive slowing) limit enthusiasm; misuse potential is non-zero but lower than benzodiazepines. Gabapentin has less specific anxiety evidence but is used adjunctively.

Tricyclic antidepressants (TCAs)

Clomipramine and imipramine have established evidence in panic disorder; amitriptyline in GAD. Older but effective third-line option after SSRI/SNRI failures. Anticholinergic side effects, cardiac considerations (ECG before and during therapy), and lethality in overdose limit use. Reasonable in specialty psychiatric care.

Acceptance and Commitment Therapy (ACT) or schema therapy

When standard CBT has plateaued, switching modality often produces more change than another CBT round. ACT shifts focus to values-driven action despite anxiety; schema therapy addresses long-standing maladaptive patterns underlying anxiety. Effect sizes comparable to CBT in published trials; mechanism differs.

Atypical antipsychotic augmentation

Quetiapine and aripiprazole at low doses can augment SSRI/SNRI response in treatment-resistant anxiety. Trials primarily in GAD; extension to other anxiety disorders is reasonable. Metabolic side effects (weight, lipids, glucose) require monitoring; reserve for patients with adequate antidepressant trials who have plateaued.

Hydroxyzine

H1-antihistamine with anxiolytic effects, particularly useful for breakthrough anxiety. Non-addictive (unlike benzodiazepines). FDA-approved for anxiety. Sedation is the major side effect. Useful as adjunct or PRN; not typically sufficient as monotherapy in treatment-resistant cases.

When standard treatments fail

After multiple SSRI/SNRI trials, augmentation, and adequate CBT have failed, escalation includes: MAOI trial in specialty care (phenelzine has historical evidence in SAD and panic) → ketamine for the depressive symptoms or anxiety directly → intensive outpatient anxiety programs → residential anxiety treatment for severe cases → reassessment of underlying diagnosis (occult substance use, undiagnosed medical contributor, autistic spectrum, ADHD). For patients with prominent insomnia driving anxiety, addressing sleep specifically (CBT-I, melatonin agonists, low-dose trazodone) can produce substantial anxiety improvement that other interventions did not. Treatment-resistant anxiety often coexists with treatment-resistant depression and complex PTSD; integrated treatment plans that address all three simultaneously typically outperform sequential single-condition treatment.

Where ketamine fits

Ketamine in treatment-resistant anxiety has a growing but still small evidence base. The Mills 2025 BJPsych analysis of the Ketamine for Adult Depression Study (KADS) demonstrated measurable anxiety reduction alongside antidepressant effect across a diagnostically heterogeneous depressive cohort — supporting ketamine's broader anxiolytic mechanism. Single-disorder anxiety RCTs are smaller (Glue and colleagues' work in generalized anxiety, social anxiety) but consistent with the broader picture. Clinically, ketamine becomes relevant for treatment-resistant anxiety patients with comorbid depression (very common), or for those who have failed adequate trials of multiple SSRIs/SNRIs plus CBT. The depressive component often justifies ketamine even when anxiety is the patient's primary concern. Considerations specific to anxiety patients: hyperventilation-prone or panic-prone patients benefit from careful preparation about the dissociative phenomenology of ketamine; the experience can otherwise feel similar to panic-like depersonalization. Patients with predominant somatic anxiety (chest pressure, throat tightness) sometimes report ketamine sessions producing relief specifically of these somatic patterns.

Where this fits with Tovani

Tovani treats treatment-resistant anxiety in the context of comorbid depression — the depression typically serves as the primary indication and the anxiety responds via the broader anxiolytic mechanism. Patients with isolated treatment-resistant anxiety (no comorbid depression) and no adequate first-line trials are typically referred back to first-line care before ketamine is appropriate. The eligibility screening captures anxiety history, prior medication trials, and CBT history. For patients with hyperventilation-prone or panic-prone anxiety, the session preparation includes explicit education about the dissociative phenomenology of ketamine and grounding strategies; dose is adjusted carefully for these patients.

Check eligibility The science behind ketamine

Frequently asked

Is "treatment-resistant anxiety" a real diagnosis?

Not a formal DSM-5-TR or ICD-11 diagnosis — it's a clinical descriptor for anxiety that hasn't responded to adequate first-line treatments. The construct parallels treatment-resistant depression (TRD) but has less FDA-acknowledged framework. Despite the absence of formal definition, the clinical reality is widely recognized: a meaningful portion of anxiety patients do not respond to standard SSRIs and CBT.

How many medications do I have to try?

The most useful working definition parallels TRD: at least two adequate trials of anxiolytic pharmacotherapy from different mechanistic classes (typically SSRI + SNRI, or SSRI + pregabalin), plus a course of evidence-based CBT. "Adequate" means therapeutic dose, 8-12 weeks at that dose, and confirmed adherence. Many patients labeled treatment-resistant have not actually completed adequate trials.

Will ketamine help my anxiety?

The evidence base for ketamine in anxiety specifically is growing. Mills 2025 BJPsych demonstrated measurable anxiety reduction alongside antidepressant effect. Ketamine becomes more reasonable when anxiety coexists with treatment-resistant depression (very common), or after adequate trials of multiple SSRIs/SNRIs plus CBT have failed. The depressive component often justifies treatment even when anxiety is your primary concern.

What if ketamine makes my anxiety worse during the session?

Some patients with hyperventilation-prone or panic-prone anxiety initially experience the dissociative phenomenology of ketamine as panic-like. Careful preparation addresses this — explicit education about what the experience will feel like, grounding techniques before and after sessions, and dose adjustment for patients more prone to this. With preparation, most anxiety-prone patients tolerate sessions well and many find them therapeutic.

Should I stop my anxiety medication during ketamine treatment?

No — continue your existing medication unless your prescribing physician advises a change. Many patients are on stable SSRIs or SNRIs during ketamine treatment; the combination is generally safe and the antidepressant maintenance can support durability between sessions. Benzodiazepines may need timing adjustment around sessions; this is decided by the treating physician based on individual circumstances.

References

Mills NT et al. 2025, British Journal of Psychiatry — Effect of ketamine on anxiety findings from the Ketamine for Adult Depression Study (KADS) — measurable anxiety reduction alongside antidepressant effect across diagnostically heterogeneous cohort, supporting broader anxiolytic mechanism with relevance to treatment-resistant anxiety presentations. (PMID 39763417)
Bandelow B et al. 2023, World Journal of Biological Psychiatry — WFSBP guidelines for pharmacological treatment of anxiety, OCD, and PTSD disorders — current evidence base for treatment-resistant anxiety escalation including SSRIs, SNRIs, TCAs, pregabalin, and augmentation strategies. (PMID 35900161)
Bandelow B et al. 2017, Dialogues in Clinical Neuroscience — Comprehensive review of treatment of anxiety disorders — framework for sequential treatment escalation in patients who do not respond to first-line pharmacotherapy and CBT. (PMID 28867934)
Sanacora G et al. 2017, JAMA Psychiatry — APA consensus statement on ketamine in mood disorders — addresses use in anxiety-spectrum presentations including treatment-resistant anxiety with comorbid depression. (PMID 28249076)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.